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Context. Existing empirical evidence shows that continuous deep sedation until
death is given in about 15% of all deaths in Flanders, Belgium (BE), 8% in The
Netherlands (NL), and 17% in the U.K.
Objectives. This study compares characteristics of continuous deep sedation to
explain these varying frequencies.
Methods. In Flanders, BE (2007) and NL (2005), death certificate studies were
conducted. Questionnaires about continuous deep sedation and other decisions
were sent to the certifying physicians of each death from a stratified sample
(Flanders, BE: n¼ 6927; NL: n¼ 6860). In the U.K. in 2007e2008, questionnaires
were sent to 8857 randomly sampled physicians asking them about the last death
attended.
Results. The total number of deaths studied was 11,704 of which 1517 involved
continuous deep sedation. In Dutch hospitals, continuous deep sedation was
significantly less often provided (11%) compared with hospitals in Flanders, BE
(20%) and the U.K. (17%). In U.K. home settings, continuous deep sedation was
more common (19%) than in Flanders, BE (10%) or NL (8%). In NL in both
settings, continuous deep sedation more often involved benzodiazepines and
lasted less than 24 hours. Physicians in Flanders combined continuous deep
sedation with a decision to provide physician-assisted death more often. Overall,
men, younger patients, and patients with malignancies were more likely to receiveAddress correspondence to: Livia Anquinet, PhD, End-
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34 Vol. 44 No. 1 July 2012Anquinet et al.continuous deep sedation, although this was not always significant within each
country.
Conclusion. Differences in the prevalence of continuous deep sedation appear
to reflect complex legal, cultural, and organizational factors more than
differences in patients’ characteristics or clinical profiles. Further in-depth studies
should explore whether these differences also reflect differences between
countries in the quality of end-of-life care. J Pain Symptom Manage
2012;44:33e43.  2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All
rights reserved.Key Words
Continuous deep sedation until death, continuous deep sedation, palliative sedation, end-of-
life careIntroduction
Dying with dignity and without pain are
characteristics of what people consider to be
a ‘‘gooddeath.’’1e5 Although palliativemedicine
has made improvements in controlling symp-
toms at the end of life, some terminally ill pa-
tients still experience ‘‘refractory symptoms,’’
uncontrollable and unresponsive to conven-
tional therapies and optimal palliative care.6e8
As an option of last resort, palliative sedation,
that is, reducing the patient’s consciousness
and thus the awareness of suffering, may be
used.9,10 Palliative sedation can vary from mild
to deep sedation and can be used intermittently
or continuously. Continuous deep sedationuntil
death can be considered an extreme formof pal-
liative sedation; it has been described by some
(especially if accompanied by withdrawal of clin-
ically assisted hydration and nutrition) as a form
of ‘‘slow euthanasia.’’11
There appears to be significant and substan-
tial variation in the prevalence of continuous
deep sedation between countries and over
the years. A study across six European coun-
tries in 2001e2002 reported a prevalence rang-
ing from 3% (Denmark) to 9% (Italy) of all
deaths. In Flanders, Belgium (BE), its inci-
dence was estimated to be 8% and in The
Netherlands (NL) 6%.10 More recent studies
with comparable designs showed an increase
in the incidence of sedation. In Flanders, BE
in 2007, its incidence was estimated to be
15% of all deaths.12 In NL in 2005, this was
8%.13 In the U.K. in 2008, its prevalence was
17% of all deaths.14 Further details of the
methods used in these studies are given in
the section below.Continuous deep sedation until death is
a heavily debated practice with regard to its
indications and performance and also its rela-
tionship with life-shortening end-of-life prac-
tices, such as euthanasia.6,15,16 Some national
and international guidelines for the use of seda-
tion have been published to educate clinicians
and also to show patients and families that
continuous deep sedation until death is an ac-
ceptable medical end-of-life procedure.6,17e21
Official national guidelines are available in NL
and BE, respectively, presented by the Royal
Dutch Medical Association and the Federation
for Palliative Care Flanders.17,22
The causes of variation between countries in
the use of continuous deep sedation in end-of-
life care have not yet been investigated. There-
fore, we focused on three countries for which
we had the most recent and comparable
data. This study assessed Flanders, BE, NL,
and the U.K., in hospital and home settings,
for the frequency of continuous deep sedation
until death, the characteristics of patients who
received sedation, and other characteristics of
the practice to gain insights into what causes
variable rates of sedation.Methods
We conducted post hoc comparative analy-
ses using data on end-of-life decision-making
practices that were collected separately in Flan-
ders, BE,12 NL,13,23 and the U.K.14,24 Because
we had only access to data from Flanders and
not from the Walloon provinces of BE, we
will use Flanders instead of BE in the following
sections.
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Flanders and NL. In Flanders (in 2007) andNL
(in 2005), large-scale death certificate studies
were conducted.12,13,23 All deaths in these coun-
tries are reported to either the FlemishMinistry
of Public Health in BE or the central death reg-
istry of Statistics Netherlands by means of
a death certificate that is signedby the reporting
physician. Stratified samples of Flemish and
Dutch residents aged one year or older at the
time of death who died between June and
November 2007 (Flanders) or between August
and November 2005 (NL) were drawn. All
deaths that occurred in these periods were pro-
portionally stratified for month of death and
province of death (in BE, Flanders consists of
five provinces). Some deaths, however, have
a higher likelihood of being preceded by one or
more end-of-life decisions (ELDs).25,26 There-
fore, we assigned deaths to one of four strata ac-
cording to cause of death and corresponding
estimated likelihood of an ELD, ranging from
stratum 0: ‘‘Cause of death implies that an
ELD is certain’’ to stratum 3: ‘‘Cause of death
implies that an ELD is improbable.’’ We adop-
ted disproportionate sampling, and sampling
fractions were larger for groups in which it
was more likely that an ELD would be made.
For each sampled death certificate of nonsud-
den deaths, the attending physician was sent
a questionnaire. The response rate was 58%
(3623 of 6202 questionnaires) for Flanders
and 78% (5342 of 6860 questionnaires) for
NL.12,13,23,27United Kingdom. In theU.K., a random sample
of working U.K. medical practitioners with dif-
ferent specialties was drawn from Binley’s data-
base (www.binleys.com), a regularly updated
national database describing the medical work-
force. An initial mailing of questionnaires and
two follow-up reminders were sent between No-
vember 2007 and April 2008. Anonymity was
guaranteed.14 The response rate was 42%
(3733 of 8857 questionnaires).14,24 The death
certificate method could not be used in the
U.K. because this survey method is highly re-
stricted because of privacy legislation.28Questionnaire
In all countries, the questionnaire contained
structured questions about the end-of-lifedecision-making process. The questionnaire
was virtually identical to the ones used in pre-
vious studies.24,25,29
In Flanders and NL, the key question about
continuous deep sedation was as follows: ‘‘Was
the patient continuously and deeply sedated
until death by the use of one or more drugs?’’
Subsequently, it was asked which medication
was given for sedation and at what time before
death continuous sedation of the patient was
started. In the U.K., the sedation question
was as follows: ‘‘Was the patient continuously
and deeply sedated until death or kept in
a coma before death?’’ Subsequently it was
asked which medication was given for sedation
and at what time before death continuous se-
dation of the patient was started.
The question about physician-assisted death
(PAD) in all countries was as follows: ‘‘Was death
caused by the use of a drug prescribed, sup-
plied, or administered by you or a colleague
with the explicit intention of hastening the
end of life (or of enabling the patient to end
his or her own life)? If yes, who administered
this drug (i.e., introduced it into the body)?’’
For Flanders, NL, and the U.K., PAD includes
euthanasia, physician-assisted suicide, and life
shortening not on request. Patients’
sociodemographic characteristics (sex, age,
cause and place of death) were collected from
the death certificates for Flanders and NL and
from the questionnaires for the U.K.
Statistical Analysis
The percentages reported for Flanders and
NL were weighted to adjust for the dispropor-
tionate case sampling and differences in re-
sponse rates in relation to the patient’s sex,
age, province (Flanders), marital status (NL),
region of residence (NL), and place and cause
of death. After adjustment, the percentages
were extrapolated to cover a 12-month period
to reflect all deaths in Flanders in 2007 and NL
in 2005. For U.K. analyses, all data were
weighted by both physician specialty and cause
of death to make these mirror national propor-
tions, except where indicated otherwise. Also,
data were weighted to adjust for the fact that
different physicians attend different numbers
of deaths per annum. Data were analyzed us-
ing SPSS (SPSS, Inc., Chicago, IL). For the
comparison between and within countries, we
calculated 95% confidence intervals (CIs).
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Characteristics of Deaths
The total number of studied deaths was
11,704 (Table 1). The U.K. sample contained
more people of younger age (<80 years)Table 1
Characteristics o
Variables Flanders
Number of deaths per yeara 54,880
Response percentage 58
Number of studied cases 3623
Sex
Male 50 (48e52)
Female 50 (48e52)
Ageb
1e64 17 (16e19)
65e79 33 (31e35)
$80 50 (48e52)
Cause of deathc
Malignancies 29 (29e30)
Cardiovascular 34 (32e35)
Respiratory 12 (11e13)
Nervous system 4 (3e4)
Other 22 (20e23)
Place of deathd
Hospital 50 (48e52)
Home 24 (22e25)
Other 27 (25e28)
NL ¼ The Netherlands; BE ¼ Belgium.
Data are weighted % (95% CI). In Flanders and NL, percentages are weighte
weighted for physician’s specialty and cause of death. Also, data were weigh
numbers of deaths per annum. Note: Flanders is a region of BE.
Missing cases, Flanders (n): place of death (1). Missing cases, NL (n): sex (868)
cases, U.K. (n): sex (60), cause of death (178), and place of death (16).
aFlanders data are for 2007; NL data are for 2005; and the U.K. data are for
bDeaths of infants younger than one year were not included in the samples fo
the U.K., age group 1e64 was 1e69 years and age group 65e79 was 70e79 y
cCerebrovascular disease is included in cardiovascular diseases for Flanders, N
dIn Flanders, hospital includes hospital deaths; home includes deaths in own h
homes and other places not specified. In NL, hospital includes hospital death
of death includes deaths in care homes, nursing homes, and other places not s
home includes deaths in own home of deceased; and other place of death inc
in hospital or home.(60%) compared with Flanders (50%) and
NL (52%). In all countries, cardiovascular
and malignant diseases were the most frequent
causes of death. In the U.K., there were signif-
icantly more people dying from nervous sys-
tem diseases (8%) than in Flanders (4%) and
NL (3%). Patients more often died in a hospi-
tal in the U.K. (83%) than in Flanders (50%)
and NL (32%).
Frequency of Continuous Deep Sedation
The total number of deaths involving contin-
uous deep sedation until death was 1517
(Table 2). Continuous deep sedation was used
less frequently in NL (8%) than in Flanders
(15%) and the U.K. (17%). Sedation was signif-
icantly less often performed in Dutch hospitals
(11%) compared with Flanders (20%) and the
U.K. (17%) and significantly more often at
home in the U.K. (19%) compared withf Deaths
NL U.K.
13,0870 579,697
78 42
5239 2842
49 (47e50) 50 (46e53)
51 (50e53) 50 (47e54)
19 (18e20) 33 (30e37)
33 (31e34) 27 (24e30)
49 (47e50) 40 (37e43)
29 (28e30) 27 (24e30)
32 (31e34) 34 (30e37)
11 (9e12) 13 (11e16)
3 (2e3) 8 (6e10)
26 (24e27) 18 (15e20)
32 (31e34) 83 (81e85)
28 (26e29) 10 (9e12)
40 (39e42) 7 (6e8)
d for stratification and nonresponse. In the U.K., percentages are
ted to adjust for the fact that different physicians attend different
, age (818), cause of death (987), and place of death (837). Missing
2008.
r all countries (NL [1% (n¼ 122)] and the U.K. [1% (n¼ 27)]). In
ears.
L, and the U.K.
ome of deceased; and other place of death includes deaths in care
s; home includes deaths in own home of deceased; and other place
pecified. In the U.K., hospital includes hospital and hospice deaths;
ludes deaths in care homes and deaths not categorized as occurring
Table 2
Frequency of Continuous Deep Sedation
Variables Flanders NL U.K.
Number of studied
cases
561 501 455
All settings 15 (13e16) 8 (7e9) 17 (14e19)
Hospital 20 (17e22) 11 (9e13) 17 (14e20)
Home 10 (8e12) 8 (7e9) 19 (13e25)
Other 9 (8e12) 6 (5e7) 7 (3e11)
Data are weighted % (95% CI).
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NL, sedation was significantly less often per-
formed for patients dying at home than in the
hospital, respectively, 10% vs. 20% (Flanders)
and, respectively, 8% vs. 11% (NL). In the
U.K., these percentages were not significantly
different (19% vs. 17%).Characteristics of Patients Who Received
Continuous Deep Sedation
Continuous deep sedation was most often
administered to patients younger than 80 years
in all countries and both settings (hospital:
67%e74%; home: 73%e77%) (Table 3). In
hospitals in all countries, sedation was most of-
ten performed for malignancies (28%e32%)
and cardiovascular diseases (22%e29%), in
rather comparable frequencies. At home, ma-
lignancy was the cause of death in most deaths
that involved sedation (74%e86%). This didTable 3
Characteristics of Patients Who Receiv
Variables
Hospital
Flanders NL
Number of studied cases 270 176
Sex
Male 52 (45e59) 58 (48e67) 59 (
Female 48 (45e55) 42 (33e52) 41 (
Agea
1e64 26 (21e32) 27 (20e35) 49 (
65e79 41 (34e48) 45 (36e55) 25 (
$80 33 (26e40) 28 (20e38) 26 (
Cause of deathb
Malignancies 30 (29e32) 32 (25e40) 28 (
Cardiovascular 29 (25e33) 22 (15e31) 24 (
Respiratory 15 (11e19) 9 (4e19) 16 (
Nervous system 4 (2e7) 2 (1e6) 9 (
Other 23 (17e29) 35 (27e46) 22 (
Data are weighted % (95% CI).
Number of studied cases (n) in all settings: Flanders (561), NL (501), and th
aIn the U.K., age group 1e64 was 1e69 years and age group 65e79 was 70e
bU.K. cause of death: weighted by specialty only.not differ significantly between the countries
studied.Characteristics of Continuous Deep Sedation
Medication. In all countries, benzodiazepines
(sometimes combined with opioids and/or
other drugs) weremore often used than opioids
alone to induce continuous deep sedation, es-
pecially in the home setting (Table 4). This
was statistically significant for Flanders and the
U.K. InNL, the proportion inducedwith benzo-
diazepines (sometimes combined with opioids
and/or other drugs) was higher than in Flan-
ders and theU.K. but only reached statistical sig-
nificance for NL compared with Flanders. For
the home setting, these proportions were 89%
(NL) vs. 72% (Flanders) and 81% (U.K.) and
for the hospital setting, 76%, 55%, and 58%,
respectively.Duration. Continuous deep sedation lasted,
in most cases, for one week or less in all coun-
tries and both settings (hospital: 90%e93%;
home: 91%e96%). In both settings, sedation
was more likely to last for less than 24 hours
in NL (hospital: 54%; home: 43%) compared
with Flanders (hospital: 35%; home: 27%)
and the U.K. (hospital: 38%; home: 20%).
This reached statistical significance for NL
compared with Flanders.ed Continuous Deep Sedation
Home
U.K. Flanders NL U.K.
296 190 180 119
50-68) 50 (42e58) 58 (50e66) 52 (37e68)
33e50) 50 (42e58) 42 (34e50) 48 (33e64)
40e58) 29 (23e35) 38 (31e46) 45 (28e61)
18e32) 44 (36e53) 39 (32e47) 31 (18e45)
19e34) 27 (20e36) 23 (16e31) 24 (14e34)
20e37) 78 (76e81) 86 (76e92) 74 (64e84)
17e32) 13 (9e18) 4 (1e12) 13 (6e20)
9e22) 0 3 (1e10) 5 (0e9)
2e16) 4 (2e8) 2 (0e7) 4 (0e9)
15e29) 5 (2e14) 6 (2e15) 4 (1e7)
e U.K. (455).
79 years.
Table 4
Characteristics of Continuous Deep Sedation
Variables
Hospital Home
Flanders NL U.K. Flanders NL U.K.
Number of studied cases 270 176 296 190 180 116
Medication
Benzodiazepines, opioids, and/or
other
55 (48e62) 76 (66e83) 58 (49e67) 72 (63e79) 89 (82e93) 81 (71e90)
Only opioids 28 (22e35) 16 (10e25) 22 (15e29) 25 (18e33) 9 (5e16) 17 (7e26)
Opioids and other (excluding
benzodiazepines)
10 (6e15) 3 (1e10) 12 (6e18) 3 (1e9) 2 (1e6) 3 (0e7)
Only other 7 (4e12) 5 (2e12) 8 (4e12) 1 (0e4) 0 0
Duration
0e24 hours 35 (28e42) 54 (44e63) 38 (29e47) 27 (21e33) 43 (36e51) 20 (2e38)
1e7 days 55 (48e62) 36 (27e45) 55 (46e64) 64 (56e72) 53 (45e61) 73 (56e90)
>1 week 10 (7e16) 11 (6e18) 8 (3e12) 9 (5e18) 4 (2e8) 8 (0e15)
In conjunction with PADa 10 (7e15) 3 (1e6) 1 (0e3) 19 (13e27) 8 (5e14) 3 (0e8)
PAD ¼ physician-assisted death.
Data are weighted % (95% CI).
Number of studied cases (n) in all settings: Flanders (561), NL (501), and U.K. (455).
Missing cases: U.K. hospital (n): Medication (29), Duration (29).
aFor Flanders, NL, and the U.K., PAD includes euthanasia, physician-assisted suicide, and life shortening not on request.
Table 5
Determinants of Continuous Deep Sedation in
Flanders, NL, and the U.K.
Beta SE Odds Ratios 95% CI
Sex
Male 1.00 1.00e1.00
Female 0.07 0.02 0.93 0.90e0.97
Agea
1e64 1.00 1.00e1.00
65e79 0.05 0.03 0.95 0.90e1.00
$80 0.26 0.03 0.78 0.74e0.82
Cause of death
Malignancies 1.00 1.00e1.00
Cardiovascular 1.14 0.03 0.32 0.30e0.34
Respiratory 0.99 0.04 0.37 0.34e0.40
Nervous system 0.02 0.05 0.98 0.89e1.10
Other 0.50 0.03 0.61 0.58e0.64
Place of death
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a Decision for Physician-Assisted Dying. In Flan-
ders, in both settings, sedation was more often
performed in conjunction with physician-
assisted dying. In hospitals, these percentages
were 10% of all sedated patients for Flanders,
3% for NL, and 1% for the U.K. In home set-
tings, they were 19%, 8%, and 3%, respectively.
Determinants of Continuous Deep Sedation
Multivariate logistic regression analyses
(Table 5) showed that, for all countries com-
bined, the likelihood of receiving continuous
deep sedation until death was significantly
higher for males, younger patients, patients dy-
ing of malignant diseases (apart from those dy-
ing of diseases of the nervous system), and
patients dying in the hospital. Furthermore,
Dutch patients were significantly less likely to
be sedated than both Flemish and U.K.
patients.Hospital 1.00 1.00e1.00
Home 0.62 0.62 0.54 0.51e0.56
Other 0.58 0.58 0.56 0.54e0.59
Country
Flanders 1.00 1.00e1.00
NL 0.56 0.56 0.57 0.52e0.63
U.K. 0.10 0.10 0.90 0.79e1.04
Data are weighted % (95% CI). Model summary results: Nagel-
kerke R square¼ 0.060; percentage correctly predicted¼ 91.5%.
Nonsudden deaths, all countries together. Missing cases: sex (58)
and cause of death (171).
Significant relationships are in bold face.
aIn the U.K., age group 1e64 was 1e69 years and age group 65e79
was 70e79 years.Discussion
Summary of Main Findings
Continuous deep sedation until death pre-
ceded about 15% of all deaths in Flanders,
8% in NL, and 17% in the U.K.12e14,23 Our fur-
ther analysis of the combined data from these
studies adds new information about the nature
of variations between these countries and thelikely causes of this. First, we found differences
between settings. The prevalence of continu-
ous deep sedation in hospitals is significantly
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and the U.K. In the home setting, its preva-
lence is higher in the U.K. than in the other
two countries. Our multivariate analysis for
all countries combined shows that males, youn-
ger patients, and those dying of malignancies
are more likely to receive sedation, but
between-country breakdowns of these variables
revealed few significant differences between
countries. However, there were differences
between countries in other characteristics of
sedation. In NL, sedation was more often
performed with benzodiazepines (sometimes
combined with opioids and/or other drugs)
and was particularly likely to occur in only
the last 24 hours of life. In Flanders, sedation
was more likely to be provided in conjunction
with physician-assisted dying than in the other
countries.
Strengths and Limitations of the Study
This study presents a detailed statistical over-
view of variations in the use of continuous deep
sedation between three European countries. A
major strength of our study is the similar termi-
nology and questions used that permit compa-
rability between countries (we have pointed
out instances where there were minor question
wording differences). By providing the samede-
scriptive definition of the practice (continuous
deep sedation until death), weminimized possi-
ble differences in how physicians perceived the
practice on which they had to report. However,
we focused only on one specific type of sedation
(‘‘continuous’’ and ‘‘deep’’ and ‘‘until death’’),
rather than the full range of practices that in-
volve sedation. The large random samples, the
acceptable response rates, and the guarantee
of anonymity of both physicians and patients
also strengthen the validity and reliability of
our results.
A limitation concerns the representativeness
of the results when comparing samples drawn
from death certificates in Flanders and NL
and a sample of U.K. physicians recollecting
the last death they attended. We corrected
for this by weighting the U.K. data by the num-
ber of patients each doctor normally attended
in a year and calculating CIs accordingly so
that the U.K. results could be presented as
a proportion of deaths.30 Because we used a de-
scriptive definition of continuous deep seda-
tion, it is possible that respondents includedpatients where sedation was an unintended
side effect of the drugs given. This may have
led to an overestimation of the number of
deaths involving continuous deep sedation.
Further, in BE, our study was only performed
in a specific region (Flanders), so we cannot
say if our results can be extrapolated to the
whole country. Lastly, our study only provides
information from the physician’s perspective;
its retrospective character might imply a possi-
ble recall bias, particularly for the U.K. data,
where information from death certificates
was not available and had to be recalled from
memory and, because of the short question-
naire, in-depth case analyses were impossible.
Comparison With Existing Literature
Wide variation in the prevalence of sedation
for patients nearing death has been found by
studies in different countries, ranging from
3% to 60%.10,31e35 Although much of this var-
iation will have been an artifact of the wording
of questions referring to this practice, it is
plausible that true variation exists, and our sur-
veys have confirmed this. The view that this is
a result of large differences in underlying de-
mographic and epidemiological patterns can
be rejected. In our study, a comparable distri-
bution across countries was found with regard
to sex, age, and cause of death. Another expla-
nation could be that there are differences be-
tween countries in the type of patients that
are continuously and deeply sedated. However,
our study provides little evidence for this hy-
pothesis: in the three countries, sedation was
mostly performed with younger patients and
patients with malignancies, and intercountry
variation in this was minimal.
Our analysis reveals differences in the fre-
quency of continuous deep sedation according
to place of death: sedation was less often per-
formed in Dutch hospitals compared with Flan-
ders and theU.K. andmoreoften at home in the
U.K. compared with Flanders and NL. Patients
with severe symptoms are more likely to die in
hospitals; consequently, those patients may re-
quire continuous deep sedation more
frequently.36e38 This is supported by our multi-
variate analysis combining all countries, which
showed that patients dying at home had a lower
likelihood of sedation at the end of life com-
pared with those dying in hospital. It could be
that there are barriers to the use of sedation in
40 Vol. 44 No. 1 July 2012Anquinet et al.home settings that will only be revealed bymore
detailed research studies, although such bar-
riers do not seem to affect the U.K., where our
results show that continuous deep sedation
until death at home is more common.39,40
Our analysis also has revealed differences be-
tween the countries in how continuous deep se-
dation was provided. First, benzodiazepines
(sometimes combined with opioids and/or
other drugs) weremost often used for sedation,
but this was most common in NL. Other studies
have shown benzodiazepines to be the drugs of
first choice for providing sedation in palliative
care settings.32,35,40e42 Since the introduction
of the National Palliative Sedation guideline
in 2005 in NL, there has been an increase
from 70% to 90% in the use of benzodiazepines
for sedation among Dutch physicians, suggest-
ing a growing compliance with existing guide-
lines and criteria of due care for sedation.17,43
In BE, a national guideline was introduced
only recently, and after the conduct of our study,
andnoofficial guidelines are currently available
in the U.K.22 It also is possible that Dutch physi-
cians’ expertise in deciding the indications, and
choosing the medication, for providing contin-
uous deep sedationhas improved over time. It is
possible that Dutch respondents to our survey
had a stricter understanding of the concept of
‘‘palliative sedation.’’ Unlike Flemish and U.K.
respondents, they may have been less willing
to report that continuous deep sedation had
occurred in situations where morphine was
administered, causing drowsiness but without
an explicit intention to sedate. The differences
in understandings between countries and care
settings and how these influence decision
making and practice are the focus of the UNBI-
ASED study (U.K.eNetherlandseBelgium
InternAtional SEDation study), part of the Eu-
ropean Association for Palliative Care Research
Network.44
Second, the shorter duration of sedation in
NL deserves comment, as it suggests that contin-
uous deep sedation is used by Dutch physicians
as an option of last resort when all other treat-
ments have failed, as is advised in the Dutch
guidelines.17 This alsomay explain the lower fre-
quency of continuous deep sedation in NL.
Third, continuous deep sedation wasmost of-
ten performed in conjunction with PAD in Flan-
ders, compared with NL and the U.K., for both
home and hospital settings. This suggests thatthe distinction between continuous deep seda-
tion and PAD in Flanders is less clear than in
NL, where euthanasia also is legal, or than in
the U.K., where PAD is not legal.
Finally, we found in our study that ‘‘country’’
was an important factor in predicting the proba-
bility of receiving continuous deep sedation,
even when correcting for other variables. This
confirms similar results in the literature and sug-
gests that cultural, social, and legal factors, aswell
as differences in the organization of health ser-
vice provision, also explain variability in the use
and provision of continuous deep sedation in
the countries we studied.10,26,35,36,45e50 It could
be that, as a result of euthanasia legislation in
NL in 2001 and in BE in 2002, physicians and pa-
tients can ‘‘choose’’ betweeneuthanasia andcon-
tinuous deep sedation until death. In the U.K.,
the high rate may be a result of the fact that
such sedation is perceived to be the only legal
‘‘last resort’’ option for a physician treating a
terminal patient with refractory symptoms. An
exploratory study in three countriesdBE, NL,
and the U.K.dalso suggests that, especially for
U.K. respondents, the patient’s clinical condi-
tion and context and environment of caredin
other words, whether people have the knowl-
edge and expertise to deal with the patient’s
symptomsdwill drive the use of sedation.49
Conclusions and Implications for Clinical
Practice and Future Research
Our study adds new information about the
nature of variation in the prevalence of contin-
uous deep sedation until death in Flanders
(BE), NL, and the U.K. We found differences
in the frequency of continuous deep sedation
according to place of death and the perfor-
mance of sedation with regard to the use of
benzodiazepines (sometimes combined with
opioids and/or other drugs), the duration of
sedation, and the use of sedation in conjunc-
tion with physician-assisted dying. ‘‘Country’’
also was an important factor in predicting the
probability of receiving sedation, suggesting
that cultural, social, legal, and organizational
factors probably play a role. This may have prac-
tical implications. There is a need for more de-
tailed intercountry comparative studies to
understand these variations and see how they
relate to the quality of end-of-life care. The
UNBIASED study comprises three linked stud-
ies in the U.K., BE, and NL and aims to
Vol. 44 No. 1 July 2012 41Continuous Sedation in Flanders, The Netherlands, and the U.K.explore decision making surrounding the appli-
cation of continuous sedation until death in
contemporary clinical practice and understand
the experiences of clinical staff and decedents’
informal caregivers of the use of continuous se-
dation until death and their perceptions of its
contribution to the dying process.44 Until the
results of this detailed research on this relatively
new practice in end-of-life care are known, exist-
ing guidelines for the use of sedatives provide
a helpful framework for clinicians to think
through the issues involved when making deci-
sions about individual patients.17,22Disclosures and Acknowledgments
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